

## Turning cancer against itself. Specific targeted therapies for cancers that still lack effective treatment options.

Tissue-selective targeted protein degradation

~80%

of patients lack genome-matched targeted options

<15%

of clinical-stage programs reach first approval

~\$879M

expected capitalized cost per program (incl. failures)

Orphan designation

lead indication · premium pricing + regulatory incentives

### THE PROBLEM

Too many oncology patients still lack effective targeted therapies, and many available options remain limited by **toxicity**. The bottleneck is not finding activity, it is maintaining enough **specificity** to create therapies that are both effective and tolerable.

### THE OPPORTUNITY

Solving specificity creates value on both sides. **Patients** gain better-tolerated therapies with improved outcomes. **Pharma** gains differentiated, licensable assets in high-unmet-need indications with premium pricing and regulatory incentives.

### WHAT CIRCA DOES

CIRCA design **Ligand-directed degraders (LDDs): small molecules able to selectively destroy cancer driving proteins** by hijacking the cancer cell's own degradation machinery, leveraging **tumor-specific E3 ligases** to reduce off-target and off-tissue effects. Starting in orphan oncology.

### BUSINESS MODEL

**B2B: Asset-building biotech.** Build and license pre-IND or IND-ready assets to pharma partners. Value via **upfront payments, milestones, royalties**, and potential M&A. Technology platform: Core IP across different targets enables multi-program portfolio.

### LEAD PROGRAM & PIPELINE

CIR-001

**Cholangiocarcinoma (CCA) Treatment:** rare biliary tract cancer, ~8,000 cases/yr US, median OS ~12–13 mo. Orphan designation and Fast-Track Regulatory eligible.

ORPHAN

CCA → Cervical → Ovarian → Additional indications

One core asset. Multi-indication expansion

CIR-002

Undisclosed orphan cancer - early discovery

ORPHAN

One core technology. Shared IP foundation

### FINANCING

USD 750K


ROUND SIZE

USD 250K

SEEKING

67%

COMMITTED

Lead investor: 

**Use of funds:** in vitro PoC, selectivity validation, lead-series selection, IP strengthening

### MILESTONES

M0–M9

In silico design → first-gen LDDs synthesized  
► NOW

M9–M15

In vitro degradation MoA

M15–M21

Functional activity + selectivity window

M21–M33

Lead selection + PK + In vivo PoC

### WHY CIRCA WINS

- ◆ Specificity as first principle: reduced off-target and off-tissue by design
- ◆ Orphan lead: premium pricing, regulatory incentives, market exclusivity
- ◆ Core IP scales across targets: platform value beyond lead program
- ◆ Built for partnering: assets and data packages, not just science

### THE TEAM



**Mariela Bollini**

Co-founder & CEO

PhD Medicinal Chemistry · MBA Cand.



**Alejandro Cristóbal**

Co-founder & CSO

PhD Organic Chemistry



**Maximiliano Sánchez Lamas**

Co-founder, COO & CTO

PhD Molecular Biology · MBA Cand.

